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Abstract
Background: We have developed a manufacturing strategy that can improve the safety and genetic stability of
recombinant live-attenuated chimeric dengue vaccine (DENVax) viruses. These viruses, containing the pre-membrane (prM)
and envelope (E) genes of dengue serotypes 1–4 in the replicative background of the attenuated dengue-2 PDK-53 vaccine
virus candidate, were manufactured under cGMP.
Methodology/Principal Findings: After deriving vaccine viruses from RNA-transfected Vero cells, six plaque-purified viruses
for each serotype were produced. The plaque-purified strains were then analyzed to select one stock for generation of the
master seed. Full genetic and phenotypic characterizations of the master virus seeds were conducted to ensure these
viruses retained the previously identified attenuating determinants and phenotypes of the vaccine viruses. We also assessed
vector competence of the vaccine viruses in sympatric (Thai) Aedes aegypti mosquito vectors.
Conclusion/Significance: All four serotypes of master vaccine seeds retained the previously defined safety features,
including all three major genetic loci of attenuation, small plaques, temperature sensitivity in mammalian cells, reduced
replication in mosquito cell cultures, and reduced neurovirulence in new-born mice. In addition, the candidate vaccine
viruses demonstrated greatly reduced infection and dissemination in Aedes aegypti mosquitoes, and are not likely to be
transmissible by these mosquitoes. This manufacturing strategy has successfully been used to produce the candidate
tetravalent vaccine, which is currently being tested in human clinical trials in the United States, Central and South America,
and Asia.
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Introduction
The dengue virus (DENV) complex, genus Flavivirus, comprises
four distinct serotypes of viruses (DENV-1 to -4). DENV causes the
most rapidly spreading mosquito-borne human viral disease in the
world. About 50–100 million new dengue infections occur each year
in more than 100 endemic countries [1], with an estimated 500,000
cases exhibiting hemorrhagic manifestations [1,2]. DENV infection
can cause subclinical disease or overt illness ranging from mild
dengue fever to life threatening dengue hemorrhagic fever (DHF) or
dengue shock syndrome (DSS). Infection with one DENV serotype
usually provides life-long immunity to the same serotype, but it does
not elicit long-term cross-protective immunity against other
serotypes. People with a previous DENV infection have a higher
risk of developing more severe disease in a subsequent infection with
a different serotype of DENV [3]. It has been shown that non-
neutralizing cross-reactive antibodies bound to DENV enhances
viral entry into Fcc-receptor-bearing cells, resulting in increased
virus load and/or production of certain cytokines that can increase
viral infection and pathogenesis [4]. Therefore, the ideal DENV
vaccine should provide simultaneous protection against all four
serotypes of DENV.
We have developed a tetravalent recombinant live-attenuated
dengue vaccine (DENVax) that is currently being tested in Phase 1
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and Phase 2 human clinical trials. This vaccine consists of 4
serotypes of recombinant vaccine viruses, designated as DENVax-
1, -2, -3, and -4. The preclinical research-grade viruses were
developed using reverse genetic technology at the Division of
Vector-Borne Diseases (DVBD), Centers for Disease Control and
Prevention (CDC) [5–7], while the commercial-grade DENVax
vaccine viruses were re-derived by Inviragen Inc. in collaboration
with the CDC [7], in a cGMP facility at Shantha Biotechnics Ltd.,
Hyderabad. The infectious clone-derived DENVax-2 is based
upon an attenuated DENV-2 strain, DEN-2 PDK-53 [8–11]. The
DENVax-1, -3 and -4 are chimeric, recombinant viruses that were
originally designated as D2/1-V, D2/3-V, and D2/4-V (research-
grade) [6] and express DENV-1, -3, and -4 serotype-specific prM
and E viral proteins, respectively, in the common genetic
background of the attenuated DENVax-2. The major attenuation
loci, nucleotide 59NCR-57-T, NS1-53-Asp, and NS3-250-Val, of
the DENV-2 PDK-53 vaccine have been previously determined,
and all of them are shared by the common PDK-53 virus-specific
genetic background of the four DENVax viruses [6,12]. The
genetic sequence of the three attenuation loci as well as the
previously established in vitro and in vivo attenuation phenotypes of
these vaccine candidates were carefully monitored for the cGMP-
manufactured DENVax seeds. This report describes the strategies
used to generate the master virus seeds (MVS) as well as their
genetic and phenotypic characterization. These MVS can be used




All animal experiments were conducted in accordance with the
‘‘Public Health Service Policy on Humane Care and Use of
Laboratory Animals’’ by NIH, ‘‘Animal Welfare Act and
Amendments’’ by USDA, ‘‘Guide for the Care and Use of
Laboratory Animals’’ by National Research Council (NRC),
‘‘Occupational Health and Safety in Care and Use of Research
Animals’’ by NRC, and ‘‘Biosafety in Microbiology and Biomed-
ical Laboratories’’ by CDC. The animal experimental protocol
was approved by the DVBD/CDC Institutional Animal Care and
Use Committee.
Viruses and Cells
DENV-1 16007, DENV-2 16681, DENV-3 16562, and DENV-
4 1034 served as wild type (wt) DENV controls, and they were the
parental genotype viruses for the DENVax viruses. DENVax
progenitor research-grade viruses, designated as D2/1-V, D2
PDK-53-VV45R, D2/3-V, and D2/4-V, were prepared previ-
ously [6,12]. Vero (African green monkey kidney) cells used for
making the cell banks for vaccine production originated from the
American Type Culture Collection CCL81 cell line that has been
characterized by the World Health Organization (WHO) for
manufacturing vaccines (WCB-Vero cells).
Derivation of Live Recombinant DENVax Viruses from
cDNA Clones
The engineered DENV infectious cDNA clones, pD2-PDK-53-
VV45R, pD2/1-V, pD2/4-V, and in vitro-ligated pD2/3-V,
containing the full genome-length viral cDNAs, were used to make
fresh viral RNA transcripts by in vitro transcription as described
previously [6,12]. The RNA transcripts were treated with DNase I
followed by low-pH phenol/chloroform extraction and ethanol
precipitation to remove the template cDNA and proteins. Each
sample was estimated to yield 2–4 ug of genome-length viral RNA
that could produce over 5 log10 pfu/ml of the viruses after
transfecting into 46107 Vero cells by electroporation using the
Gene Pulser Xcell total system (BioRad Laboratories). Transfected
cells were cultured in 30 ml of cell growth medium (MEM with 10%
FBS), and incubated at 36uC61uC, 5% CO2 for 6 to 11 days. These
passage 1 (P1) virus seeds were harvested, clarified by centrifugation,
stabilized, and stored in small aliquots below 260uC.
Manufacture of DENVax Master Virus Seeds
The P1 virus seeds were used to propagate DENVax pre-master
and master virus seed (MVS) lots through a strategy designed to
ensure the optimal genetic stability and safety of the manufactured
vaccines. This strategy included three serial plaque purifications,
as well as genetic analyses of viruses to select the optimal clonal
virus for continued seed production (Table 1). Briefly, the P1 seeds
were amplified once in Vero cells at a MOI of 0.001 to generate
the P2 seeds. The P2 seed stocks were evaluated by plaque
morphology and complete viral genomic sequencing. The
genetically confirmed P2 stocks were plated on Vero cells with
overlay medium as described in the plaque assay below to generate
well-isolated plaques, and six individual plaques from each
serotype of DENVax were isolated (plaque clone A–F) and mixed
into 0.5 ml of culture medium (P3). Each plaque suspension was
subjected to two additional rounds of plaque purification, resulting
in twice- and thrice-plaque purified virus seeds at passages P4 and
P5, respectively. The P5 viruses were amplified through two
sequential Vero passages to produce P7 seed stocks.
Genetic analysis of the three major DENVax attenuation loci
[6,12] and plaque phenotype analysis were conducted to screen all
24 P7 seeds. Seeds possessing appropriate initial characteristics
were further characterized by full genomic sequencing. Based on
the presence of the 3 major DENV-2 PDK-53 attenuating loci,
minimal genomic sequence alterations, and expected plaque
phenotype, one P7 clone of each serotype was selected to be the
pre-master seed. The MVS (P8) was then generated by a one-
passage amplification of the pre-master seed at MOI of 0.001 in
multiple 175 cm2 flasks of Vero cells. The MVS stocks were
harvested at 6–10 days post infection (pi), clarified by centrifuga-
tion, stabilized by the addition of serum or F127 (a pluronic block
copolymer), trehalose and human albumin [13], and stored as 1-
ml aliquots below 260uC.
Author Summary
Transmitted by Aedes spp. mosquitoes found worldwide,
dengue is the most important mosquito-borne viral
disease in the world. The incidence of dengue has
increased 30-fold over the past 50 years, and is now
endemic in over 100 countries. Vaccination is believed to
be one of the most effective strategies in dengue
prevention. However, no vaccine is currently available,
and prevention strategies to control mosquitoes in
endemic areas have been insufficient in controlling
dengue. We have developed a recombinant live-attenuat-
ed tetravalent vaccine against all four serotypes of dengue
virus. This candidate vaccine is currently under human
clinical evaluation. In this report, we provide information
regarding our manufacturing strategy, and present details
of the genetic and biological characterization of the
master seed virus for each vaccine serotype. The study
described here, our previously reported and ongoing pre-
clinical studies, and current clinical trials will provide
critical information to evaluate the safety and efficacy of
the vaccine to protect humans against dengue.
Production and Analysis of Tetravalent DENVax
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Virus Plaque Assay
Virus titers and plaque sizes were measured by plaque assay
using Vero cells as previously described [5]. For accurate
comparison, plaque sizes of all viruses were measured and
compared in the same experiment. After visualization with neutral
red on day 9 pi, up to 10 well isolated plaques for each virus were
measured for mean plaque size calculation. Fewer plaques were
measured for wt DENV-1, -3, and -4, whose larger plaque sizes
often did not permit measurement of 10 well-separated plaques.
Genetic Sequence and Taqman-based Mismatch
Amplification Mutation Assay
Viral RNA was extracted from DENVax seeds and used for
cDNA amplification as previously described [5,6]. Automatic
sequencing of the cDNA was conducted on the 3130xl Genetic
analyzer (Applied Biosystems), and results were analyzed using
Lasergene SeqMan software (DNAStar, Inc).
Taqman-based mismatch amplification mutation assay (Taq-
MAMA), a quantitative single nucleotide polymorphism assay, was
previously developed to permit finer assessment of the level of
reversion at the 59NC-57 locus of attenuation [14], and was
further optimized for this study. The specific forward primers used
to detect DENV-2 wt and vaccine sequences were D2-41-GC and
D2-40-TT, respectively. Triplicate reactions for each wt- and
vaccine-specific assay were conducted for each sample, and
specificity of the assay was confirmed by testing each RNA
standard with the heterologous genotype primer/probe sets to
ensure minimum cross-reactivity in every experiment. The real
time RT-PCR was performed with the iQ5 or CFX-95 system
(BioRad), using a BioRad iScript RT-PCR (for probes) kit. The
results were reported as the percentage of viral genomes showing
reversion. Previously, due to higher cross-reactive backgrounds
that limited the input RNA levels for this assay, the detection
sensitivity was at 0.1% reversion (discrimination power) [14]. In
this study, the assay has been further optimized using improved
equipment and reaction kits, and the cross-reactive background
was decreased considerably at much higher levels (7–8 log10
copies) of RNA template input. This optimization resulted in
significant improvement of the detection sensitivity, down to 0.01–
0.07% reversion.
Virus Replication in Mosquito C6/36 Cells and
Temperature Sensitivity in Mammalian Vero Cells
The replication phenotypes of the DENVax MVS stocks were
compared with their parental wt DENVs in C6/36 mosquito cells
(Aedes albopictus) and Vero cells grown in 6-well plates. Cells were
infected at a MOI of 0.001 and incubated with DMEM medium
containing 2% FBS in a 5% CO2 incubator at 28uC (C6/36), or
37uC and 39uC (Vero). Aliquots of the culture supernatant were
collected for each virus on day 5 (Vero) or 6 (C6/36) pi, mixed
with an equal volume of medium containing 40% FBS, and stored
at 280uC until processed by plaque titration. All samples were
tested in duplicate for each experiment.
Mosquito Infection, Dissemination, and Transmission
Aedes aegypti mosquitoes used for this study were from a colony
established in 2002 from a village near Mae Sot (169N, 339E),
Thailand. Five-to-seven day old female mosquitoes were used for
infectious blood meal feeding or intrathoracic (IT) inoculations.
Aliquots of freshly cultured DENVax and wt DENV were used
immediately upon harvest (without any freeze-thaw cycle) to make
virus blood meals, and the remaining virus suspensions were
supplemented with 20% FBS and stored at 280uC for plaque
titration and IT inoculation. The DENVax seeds for these
experiments were prepared from one passage of the pre-master
seeds in Vero cells, and were considered DENVax MVS
equivalents.
Infectious blood meals were prepared by mixing fresh virus at a
ratio of 1:1 with defribrinated chicken blood (Colorado Serum
Company). Mosquitoes were sugar-starved overnight and then
offered the blood meal for 1 hour using a Hemotek membrane
feeding system (Discovery Workshops). A 50-ml aliquot of the
blood meal was retained at 280uC for back-titration of virus
doses. Fully-engorged females were sorted under cold anesthesia
and placed into cartons with 10% sucrose solution provided ad
libitum at 28uC with a photoperiod of 16:8 h (light:dark). After 14
days, 25–30 mosquitoes from each group were anesthetized by
triethylamine (Carolina Biological Supply Company) exposure,
and one hind leg was removed and placed in 0.5 ml of DMEM
with 10% FBS and penicillin/streptomycin (100 U/ml and
100 mg/ml respectively). Saliva was collected by inserting the
proboscis of the mosquito into a capillary tube containing 2.5%
FBS and 25% sucrose solution. Mosquitoes were allowed to
salivate for at least 15 minutes and then capillary tubes and bodies
were placed into separate tubes containing DMEM. For IT
inoculation, mosquitoes were cold-anesthetized and inoculated
with approximately 50 pfu of virus in 0.34 ml inoculum. Inocu-
lated mosquitoes were kept for 7 days in the same conditions as
described above. Mosquitoes were then anesthetized, and their
saliva and bodies were collected as described above. All collected
samples were stored at 280uC until they were further processed by
plaque titration. Body and leg samples were homogenized with
Table 1. cGMP Rederivation of DENVax MVS in WCB-Vero Cells.
Passage Seed Production/Purification Characterizations
P1 Transfect WCB-Vero with transcribed viral RNAs Plaque titration
P2 Amplify P1 virus Full genome sequence and plaque phenotype
P3 Pick 6 plaques (A–F)/serotype from P2 plaque assay Plaque purification
P4 Pick plaques A–F from P3 plaque assay Plaque purification
P5 Pick plaques A–F from P4 plaque assay Plaque purification
P6 Amplify P5 A–F plaques Plaque titration
P7 Pre-master seeds: Amplify P6 A–F Full genome sequence, TaqMAMA, Plaque phenotypes
P8a MVS: Amplify selected P7 virus seed Full genetic and phenotypic characterization
aOne optimal P7 seed (A, B, C, D, E, or F) was selected based on the genetic and plaque analysis to make the P8 MVS.
doi:10.1371/journal.pntd.0002243.t001
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copper coated BBs (Crossman Corporation, NY) at 24 cycles/
second for 4 min using a mixer mill, and then clarified by
centrifugation. Saliva tubes were centrifuged at 3,0006 g for
3 minutes to expel fluid from capillary tubes. Virus plaque
titration results from bodies, legs, and saliva were used for
determining the infection, dissemination, and transmission rates,
respectively.
Mouse Neurovirulence
Timed pregnant female ICR mice were obtained from Taconic
Labs, and monitored for birth of pup litters. Approximately 12–
24 hours after birth, two litters of eight pups per virus (n = 16) in
each experiment, were challenged with 103 to 104 pfu of virus in
20 ml of diluent by intracranial (ic) inoculation using a 30-gauge
needle. Animals were monitored at least 3 times daily for at least
32 days following challenge. At the first sign of illness (rough fur,
hunched back, weight loss, abnormal movement, paralysis, or
lethargy) animals were euthanized.
Results
Production and Analysis of Pre-master DENVax Viruses
DENVax viruses were re-derived under cGMP condition by
transfection of viral RNA transcribed from the full-length
recombinant cDNA into production-certified Vero cells, resulting
in P1 virus seeds. The four P1 viruses were then amplified to
obtain P2 seeds, which were subjected to full-length genome
sequencing. Results showed that each of the four serotypes of P2
viruses was genetically identical to its homologous progenitor,
research-grade candidate vaccine virus [6]. The original plaque
phenotypes were also retained in the P2 viruses. Six plaque-
purified viruses (A–F clones) were isolated for each serotype of
DENVax from the P2 seeds, and each isolated plaque was directly
plaque purified two more times. The third plaque purification (P5)
of each virus was amplified twice in Vero cells to produce the
potential pre-master P7 DENVax seeds (Table 1). Genome
sequences and plaque phenotypes of the P7 seeds were analyzed
and compared to the P2 seeds (Table 2). Plaque phenotypes of the
P7 viruses were generally similar to those of the P2 seeds. One
virus (DENVax-2 C) had somewhat larger than expected plaques,
2 viruses were smaller (DEVax-4 E and F), and 4 viruses
(DENVax-1 C and D, DENVax-4 B and D) had slightly clearer
plaques (Table 2). Virus titers reached over 6.0 log10 pfu/ml for
most of the P7 seeds, except for 5 viruses.
We determined previously that two (NS1-53 and NS3-250) of
the three major attenuation determinants of the DENV-2 PDK-53
genetic vector are extremely stable. Genome sequencing of more
than 60 candidate vaccine virus seeds after 10 or more serial
passages in Vero cells identified no reversion event at these 2 loci
[[14] and unpublished data]. All sequence chromatograms
generated from both forward and reverse sequencing for these
two sites were very clean without any minor nucleotide
populations evident at the NS1-53 and NS3-250 genetic loci. In
contrast to the NS1 and NS3 sites, different levels of reversions at
the 59NCR-57 attenuation locus were previously identified from
multiple serially passaged research-grade vaccine viruses [14],
suggesting this locus might not be as stable as NS1 and NS3 after
multiple passages in cell culture. Therefore, a sensitive Taq-
MAMA was developed to accurately measure the reversion rate at
the 59NCR-57 locus by real-time RT-PCR [14]. Depending on
the concentration of the input viral RNA for each virus in the
assay, the sensitivity of the assay ranged between 0.01% and
0.07% reversion, which is much more sensitive than the 10–30%
reversion sensitivity limit detectable by consensus genome
sequence analysis. We found 15 of the 24 viruses had minimal
or undetectable reversion (,0.07%), 1 virus (DENVax-3 D) had
almost 100% reversion, and 8 viruses (1 DENVax-1, 1 DENVax-
2, 2 DENVax-3, and 4 DENVax-4) had partial reversion ranging
from 0.08% to 12.85% (Table 2). Full-length genome sequencing
was conducted for 16 of the 24 P7 viruses with low levels of
59NCR57 reversion as measured by TaqMAMA. All of the
sequenced viruses maintained the other 2 DENVax attenuation
determinants at NS1-53 and NS3-250, and all had acquired
additional mutations that were not present in the original,
engineered recombinant cDNA clones (Table 2). DENVax-1 A,
DENVax-2 F, DENVax-3 F, or DENVax-4 F was selected as the
most optimal pre-master seed for each serotype because their
genotypes and plaque phenotypes most closely resembled those of
the originally designed vaccine viruses [6]. These pre-master seeds
were further amplified to generate the MVS (Table 1).
Genetic Analysis of DENVax MVS
Full-length genome sequencing revealed that the MVS for
DENVax-1, DENVax-2, and DENVax-3 were identical to their
respective pre-master seeds (Table 2 and 3). The DENVax-4 MVS
acquired an additional amino acid mutation, at locus NS2A-
K99K/R (from K to K/R mixed genotype) during production of
the MVS. TaqMAMA results demonstrated that the 59NCR-57
reversion rate was minimal or undetectable in all 4 MVS lots
(Table 3).
Plaque Phenotype of DENVax MVS
Plaque phenotypes of the DENVax MVS were compared with
wt DENVs and their homologous research-grade chimeric viruses
in Vero cells (Fig. 1). All of the MVS of DENVax-1, -2, and -3
produced plaques that were significantly smaller than their wt
homologs and very similar (within 0.4-mm differences) to their
homologous research-grade viruses in Vero cells. DENVax-4
MVS was also significantly smaller than the wt DENV-4, but was
slightly larger (0.9 mm difference) than the original research-grade
D2/4-V chimera.
Temperature Sensitivity of DENVax MVS
Temperature sensitivity was tested in Vero cells for the DENVax
MVS and compared with their homologous wt and the original
research-grade chimeric vaccine virus. The wt DENV-3 16562 was not
temperature sensitive. The wt DENV-1 and DENV-4 were moder-
ately temperature sensitive at 39uC (titers were approximately 1.0 log10
pfu/ml lower at 39uC than at 37uC, Fig. 2). Wt DENV-2 16681 was
the most temperature sensitive of the wt DENVs tested, and resulted in
a 100-fold titer drop at 39uC. DENVax-1, -2, and -3 were as
temperature sensitive as their original homologous research-grade
chimeric vaccine viruses (Fig. 2). Titers at 39uC dropped between 2.0
and 3.0 log10 pfu/ml for these DENVax strains. DENVax-4 was also
temperature sensitive, demonstrating a 5-fold reduction in titer.
However, the original research-grade D2/4-V showed about 10-fold
reduction in titer. The final stabilized DENVax-4 MVS contained
pluronic block copolymer F127, and we have previously shown that
this copolymer can enhance thermal stability of the DENVs [13]. The
presence of the copolymer F127 in DENVax-4 MVS likely contributed
to the less pronounced temperature sensitivity of the virus in the Vero
culture assay. In a separate experiment, we further evaluated the
temperature sensitivity of an MVS-derived DENVax-4 strain in the
absence of F127. To remove the F127 from the strain, viral RNA was
isolated from a DENVax-4 bulk virus preparation and transfected into
Vero cells. This DENVax-4 virus appeared to be as temperature
sensitive as the D2/4 V (titer reduced 1.5 log10 pfu/ml) on day 3 pi in
the absence of F127 (Fig. 2).
Production and Analysis of Tetravalent DENVax
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DENVax MVS Replication in Mosquito C6/36 Cells
Previous studies showed that the research-grade chimeric
vaccine viruses retained the attenuation phenotype of the
backbone DENV-2 PDK53 virus in C6/36 cells [6,15]. The
DENVax MVS were grown in C6/36 cells to verify their retention
of this in vitro attenuation phenotype. Compared to the wt DENVs,
DENVax-1, DENVax-2, and DENVax-4 MVS showed marked
growth reduction (at least 3 log10 pfu/ml reduction) in C6/36 cells
on day 6 pi (Fig. 3). The DENVax-3 MVS also exhibited reduced
growth compared to the wt DENV-3 16562, but the reduction was
not as marked (1–2 log10 pfu/ml reduction). However, the titer of
the DENVax-3 was similar (within 1 log10 pfu/ml difference) to
the titer of the research-grade chimeric D2/3-V vaccine virus.
Virus Infection, Dissemination, and Transmission Rates in
Whole Mosquitoes
Oral infection experiments were conducted in Ae. aegypti mosquitoes
to evaluate the ability of DENVax to infect midgut (overcome midgut
infection barrier; MIB), disseminate to secondary tissues (overcome
midgut escape barrier; MEB), and be transmittable (release virus to
saliva). Infectious blood meals were back-titrated to measure the virus
titers and only the experiments with similar virus titers in the blood
meal (less than 1 log10 pfu/ml differences) between parental DENV
and DENVax for each serotype were included for comparisons in
Table 4. DENVax-1, DENVax-2, and research-grade D2 PDK-53-
VV45R did not infect mosquitoes through oral feeding, which was
significantly different (p,0.0001) from their parental viruses, DENV-1
16007 (44% infection) and DENV-2 16681 (43.3% infection). Since no
mosquito was infected by DENVax-1 and -2, there was no
dissemination concern for these two vaccine viruses. While DEN-
Vax-4 did infect 2 of the 55 mosquitoes through oral feeding, the
infection rate was significantly lower (p,0.05) than the wt DENV-4
1036. DENVax-3 did not infect any mosquitoes in two experiments
with blood meal viral titers of 5.260.02 log10 pfu/ml (Table 4), and in a
separate experiment with blood meal viral titer of 6.0 log10 pfu/ml,
only 1 out of 30 mosquitoes became infected (data not shown in
Table 4). However, wt DENV-3 16562 also had a very low infection
rate (8%) at 5.2 log10 pfu/ml, and the rate did not increase in a separate
experiment with a higher blood meal viral titer at 6.2 log10 pfu/ml (3%,
1 positive out of 30 mosquitoes). Although the wt DENV-3 and
Table 2. Characterizations of pre-master (P7) seeds.
Virus Clonea TaqMAMAb Log10 pfu/ml Plaque
c Mutations identified in genomed
DENVax-1 A ** 6.85 P2 NS2A-I116L, NS2B-E92D, one silent
B * 6.93 P2 nde
C * 6.93 D nd
D ** 7.02 D C-K67A; one silent
E 0.57% 7.28 P2 nd
F ** 7.18 P2 E-T473M; one silent
DENVax-2 A 0.03% 6.33 P2 NS1-K341N
B * 6.33 P2 E-K305T, two silent
C * 5.84 L NS4A-T18A, four silent
D 0.08% 6.20 P2 NS2B-I99L, one 39NCR
E 0.03% 6.31 P2 prM-K52E, NS5-I412V, two silent
F ** 6.15 P2 prM-K52E, NS5-I412V
DENVax-3 A * 6.00 P2 NS5-K200N, one silent, one 39NCR
B 0.05% 6.27 P2 NS2A-I33T, NS2A-M59T
C 0.30% 6.25 P2 nd
D 100.00% 6.27 P2 nd
E 0.31% 6.00 P2 nd
F ** 6.30 P2 E-T223S, one silent
DENVax-4 A 0.47% 5.60 P2 E-K323R/K, NS2B-L21F/L, NS2B-T39S, one silent
B * 5.65 D NS2A-A126V; NS4A-N5D; NS5-K383R, one silent
C 4.50% 5.90 P2 nd
D 12.85% 5.97 D nd
E 0.52% 6.85 S prM-E85D, NS2B-T45A, NS5-M320T, NS5-E551G, two silent
F 0.02% 6.93 S NS2A-D66G, NS4A-A21V, four silent
aCloned viruses (by serial plaque purifications) selected for further development of MVS are designated in bold.
b*: Reversion rate ,0.07% (detection limit).
**: Reversion rate ,0.01% (detection limit).
cPlaque phenotypes: P2: similar to P2 virus; L = larger than P2 virus, D = similar size, but appear somewhat different in clearness of the plaques; S = smaller than P2.
dSubstitutions differing from the engineered DENVax cDNA clones. Amino acid mutations are listed with residue position in the viral proteins. Total numbers of silent
mutation in structural and non-structural genes, as well as substitution at non-coding regions (59 or 39NCR) are also noted.
end = Not done. These clones had higher 59NCR-57 reversion rates (by TaqMAMA) than other clones, so were excluded from further sequence analysis.
doi:10.1371/journal.pntd.0002243.t002
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DENV-4 had significantly lower infection rates than the wt DENV-1
and DENV-2, the mean virus titers in the infected mosquitoes were
similar (3.1 to 3.9 log10 pfu/mosquito). In contrast, the DENVax-4
titers from the two infected mosquitoes were both minimal (0.7 log10
pfu/mosquito), which was 1,000-fold lower than the titer from the
mosquitoes infected by wt DENV-4 1036 (3.961.5 log10 pfu/
mosquito). For those mosquitoes that were infected, dissemination
out of the midgut could be assessed by determining whether virus was
present in the legs. The four wt DENVs resulted in dissemination rates
ranging between 36.3% and 62.5%, and their mean virus titers (in
log10 pfu) from the legs were between 0.960.3 and 2.260.7 (excluding
negative samples). Neither of the two DENVax-4 infected mosquitoes
resulted in virus dissemination to the legs (Table 4).
Since the oral feeding results showed minimal or no detectable
midgut infection and body dissemination by DENVax, we could not
evaluate their transmission potentials from this experiment. In
addition, while disseminated virus was detectable in the legs, none of
the four wt DENVs was detectable in saliva of orally infected
mosquitoes (not shown in Table 4) which suggested that the oral
feeding experiment may not be sufficiently sensitive to measure the
transmission rate of these DENVs. Therefore, highly stringent
artificial infections by IT inoculation were performed to directly
infect the mosquito body bypassing both MIB and MEB. Except for
DENVax-4, all viruses (wt and DENVax) achieved 100% infection
of the IT inoculated Ae. aegypti. The DENVax-4 inoculum had a
slightly lower viral titer than the other three viral inocula, but it still
successfully infected 70% of the inoculated mosquitoes (Table 4).
Despite the high body infection rates achieved by IT
inoculation, all four DENVax viruses exhibited significantly lower
(p,0.005) or non-detectable transmission rates (0–10%) compared
to the wt DENVs (43–87%, Table 4). The mean expectorate virus
titers calculated from saliva (positive samples only) were slightly
higher from wt DENV infected mosquitoes (0.9260.75 log10 pfu,
0.8860.31, 0.9660.60, and 0.8660.63, for wt DENV-1 to -4,
respectively) than those infected with DENVax (0.4060.00,
0.5560.21, 0.88 from only 1 mosquito, and none detectable, for
DENVax-1 to -4, respectively). Overall, the DENVax viruses
showed no or limited infection and dissemination after oral
feeding, and the highly stringent IT results affirmed the minimal
transmission capacity of these DENVax viruses in Ae. aegypti.
Neurovirulence in Newborn Mice
The research-grade vaccine viruses were previously shown to be
highly attenuated for neurovirulence in newborn ICR mice
maintained in-house at DVBD/CDC [5,6]. All of these mice
survived ic challenge with 104 pfu of each vaccine virus. The wt
DENV-2 16681 virus, on the other hand, resulted in 62.5%–100%
mortality in these CDC-ICR mice in various experiments. Prior to
the current study the in-house ICR mouse colony was eliminated at
DVBD/CDC. Therefore, commercial ICR mice obtained from
Taconic Labs (Taconic-ICR) were used for this study. We observed
that newborn Taconic-ICR mice were significantly more susceptible
to DENV-2 infection than the previous CDC-ICR mice. Figure 4A
summarizes the neurovirulence of wt DENV-2 16681 virus in CDC-
ICR colony (previous published and unpublished experiments) and
Taconic-ICR newborn mice challenged ic with 104 pfu of virus.
Clearly, the Taconic-ICR mice (100% mortality in 32 mice, average
survival time of 8.360.5 days) were much more susceptible to ic
DENV-2 16681 challenge than the previous CDC-ICR mice (91%
mortality in 72 mice, average survival time of 14.662.3 days).
To evaluate neurovirulence of the DENVax MVS, the Taconic-
ICR mice initially were challenged ic with a dose of approximately
104 pfu of wt DENV-2 16681, D2 PDK-53 VV45R, D2/3-V, or
DENVax 1–4 virus in one (n = 16) or two (n = 31–32) experiments
Table 3. Nucleotide and amino acid substitutions in MVS.
DENVax (Clone)a TaqMAMAb Nucleotidesc Amino Acidsd
DENVax-1 (A) ,0.07% A3823C NS2A-I116L
A4407T NS2B-E92D
A7311G silent
DENVax-2 (F) ,0.01% A592G prM-K52E
A8803G NS5-I412V
DENVax-3 (F) ,0.07% A1603T E-T223S
A7620G silent







aThe DENVax was amplified from the indicated pre-master clone.
bReversion rate at 59NCR-57.
cNucleotide position of the substitution and changes are indicated.
dMutations resulting in amino acid changes are indicated.
eMixed sequence signals were observed, indicating presence of both
genotypes.
doi:10.1371/journal.pntd.0002243.t003
Figure 1. Plaque sizes of the DENVax MVS. Mean plaque
diameters (mm) 6 SD (error bars) of the virus plaques in Vero cells
under agarose overlay measured on day 9 pi. The wt DENVs and
previously published research-grade vaccine candidate viruses were
included for control and comparison.
doi:10.1371/journal.pntd.0002243.g001
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(Fig. 4B). At this dose, D2/3-V research-grade virus, as well as
DENVax-1, and DENVax-3 MVS exhibited fully attenuated
neurovirulence phenotypes (no illness or mortality). As expected,
wt DENV-2 was uniformly fatal, with average mouse survival time
(AST) of 8.860.4 days. In these DENV-2-sensitive Taconic-ICR
mice, the D2 PDK-53-VV45R research-grade virus resulted in
Figure 2. Temperature sensitivities of DENVax MVS. Mean titers 6 SD (error bars) of the viruses replicated in Vero cells at 37uC or 39uC. The wt
DENVs and previously published research-grade vaccine candidate viruses were included for comparison. The DENVax-4 MVS contains additional F-
127 that can mask the temperature sensitivity results of the virus in this assay. A separate experiment analyzing a surrogate DENVax-4 in the absence
of F127 was also included.
doi:10.1371/journal.pntd.0002243.g002
Figure 3. Restricted growth of DENVax MVS in C6/36 cells. Mean titers 6 SD (error bars) of the viruses replicated in C6/36 cells 6 days pi. The
wt DENVs and previously published research-grade vaccine candidate viruses were included for comparison.
doi:10.1371/journal.pntd.0002243.g003
Production and Analysis of Tetravalent DENVax
PLOS Neglected Tropical Diseases | www.plosntds.org 7 May 2013 | Volume 7 | Issue 5 | e2243
81.3% mortality with AST of 11.161.1 days. The DENVax-2
MVS and DENVax-4 MVS were uniformly fatal in the Taconic-
ICR, showing AST values of 11.761.1 and 11.560.9 days,
respectively. The mortality and AST between the D2 PDK-53-
VV45R and DENVax-2 at this dose were not significantly
different (p.0.05, student t-test). The research-grade D2/4-V
was not tested at this dose for comparison with DENVax-4.
In an attempt to identify a more discriminating ic challenge dose
for those viruses that exhibited neurovirulence in the Taconic-ICR
mice, we compared the neurovirulence of wt DENV-2 16681 virus
with that of D2 PDK-53-VV45R, DENVax-2 MVS and DENVax-
4 MVS, as well as D2/4-V research-grade virus, at a 10-fold lower
dose (103 pfu, Fig. 4C). The wt DENV-2 retained a uniformly fatal
neurovirulent phenotype, with AST of 9.061.4 days, at this lower
challenge dose. The other 4 viruses exhibited intermediate
neurovirulence phenotypes, and the degree of neurovirulence was
serotype-specific. The D2 PDK-53-VV45R virus and its DENVax-
2 MVS cognate showed significant attenuation (32.3% survival with
AST of 13.863.6 days and 31.2% survival with AST of 11.563.4
days, respectively) and the differences were not significant
(p = 0.4). Both the DENVax-4 MVS and the research-grade
D2/4-V virus were highly attenuated for neurovirulence (81.3%
survival with AST of 19.465.8 days and 100% survival,
respectively). The slightly higher virulence of the DENVax-4
relative to D2/4-V was likely due to the higher virus dose that
was inoculated into the mice receiving DENVax-4 (3.4 log10 pfu)
versus the dose in the D2/4-V group (2.7 log10 pfu), based on the
back titration results of the inocula. Overall, our results indicated
that MVS of DENVax-1 and -3 exhibited complete attenuation
of neurovirulence, while DENVax-2 and -4 MVS lots retained
attenuation phenotypes that closely resembled their homologous
research-grade vaccine candidates.
Discussion
This report describes the process of re-deriving and preparing
the DENVax manufacturing seed strains under cGMP conditions,
and the genetic and phenotypic characterizations of the MVS.
Serial plaque purifications and full-genome sequence analyses
were incorporated into the manufacturing process to ensure
production of vaccine seeds with optimal safety and genetic
stability. All four of the chosen pre-master seeds had undetectable
reversion at any of the 3 attenuation loci, contained one or two
new amino acid substitutions in the viral translated proteins, and
retained the small plaque phenotypes of the previous research-
grade vaccine viruses. All of the DENVax viruses also were tested
for identity, sterility, and lack of detectable adventitious agents as
part of the manufacturing product release (data not shown). Full-
genome sequence analysis revealed that an additional amino acid
mutation evolved in the DENVax-4 MVS versus its pre-master
seed, while the other three DENVax MVS lots retained the
consensus genome sequence of their pre-master seeds. Overall,
from derivation of the P1 seeds to the pre-master (P7) seeds, only 1
or 2 non-synonymous mutations occurred in a given seed. From
P1 to MVS (P8) seeds, 2 to7 nucleotide substitutions were
identified in any given DENVax seed and only 2 to 3 of these
substitutions resulted in amino acid changes. RNA viruses are
error-prone in their genome replication, so genetic substitutions in
the flavivirus genome during cell passages are not unexpected.
None of the silent mutations in the MVS were within the 59 or
39NCR that may affect virus replication. Most of the amino acid
substitutions were very conservative (similar in residue size, pKa,
and chemistry structure). Only the change in prM-K52E of the
DENVax-2, and the substitution in NS2A-D66G of DENVax-4
were non-conservative changes. The NS2A-D66G mutation of the
DENVax-4 resides in the nonstructural gene region of the shared
DENV-2 PDK-53 genetic background. Although the NS2A-66
locus is usually D among various strains of DENV-2, interestingly
it is usually G for DENV-4. It is possible that the D to G change in
the DENVax-4 is important for fitness of the DENVax-4 in Vero
cells. The DENVax-2 prM-K52E mutation resides in the C-
terminal portion of the prM that is cleaved out from the mature
virus particles. Overall, our phenotypic characterization results
confirmed that none of the mutations in the MVS seeds
Table 4. Virus infection, dissemination, and transmission rates in whole mosquitoes.




Titerc Disseminatione Inoculum Infectionb Body Titerc Salivaf
Virus Mean±SD % (P/N) Mean±SD pd % (P/N)f pfu/dose % (P/N) Mean±SD % (P/N) pd
DENV-1 16007 6.6 44.0% (11/25) 3.661.5 36.3% (4/11) 53.9 100% (30/30) 4.760.48 43% (13/30)
DENVax-1 6.9 0% (0/30) NA ,0.0001 NA 67.8 100% (30/30) 3.460.39 10% (3/30) ,0.005
DENV-2 16681 6.6 43.3% (13/30) 3.161.5 38.5% (5/13) 67.8 100% (30/30) 5.260.34 87% (26/30)
D2 PDK53-VV45R 6.4 0% (0/30) NA ,0.0001 NA 56.4 100% (30/30) 4.060.20 0% (0/30) ,0.0001
DENVax-2 6.4 0% (0/30) NA ,0.0001 NA 52.7 100% (30/30) 3.560.27 7% (2/30) ,0.0001
DENV-3 16562 5.2 8% (2/25) 3.860.2 50% (1/2) 34.0 100% (30/30) 4.260.50 67% (20/30)
DENVax-3 5.260.02 0% (0/50) NA 0.108 NA 37.3 100% (30/30) 3.360.36 3% (1/30) ,0.0001
DENV-4 1036 5.860.5 16% (8/50) 3.961.5 62.5% (5/8) 69.4 100% (30/30) 5.260.45 70% (21/30)
DENVax-4 5.460.4 3.6% (2/55) 0.760.0 0.033 0% (0/2) 11.8 70% (21/30) 1.160.46 0% (0/21) ,0.0001
aVirus titers or Mean6standard deviation if from more than 1 experiment in blood meal (log10 pfu/ml) by back titration.
bRate of virus detected in mosquito bodies. P/N = positive/total mosquitoes.
cMean virus titers 6 standard deviation (log10 pfu/mosquito) in mosquito body. Only positive samples are included for calculation.
dStatistical analysis of the differences between wt DENV and DENVax by Fisher Exact probability.
eRate of virus detected in legs of the positively infected mosquitoes.
fRate of virus detected in saliva of the positively infected mosquitoes. Used to measure transmission efficiency.
doi:10.1371/journal.pntd.0002243.t004
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significantly altered the attenuation phenotypes of the candidate
vaccine viruses.
Our results suggested that the DENVax viruses are geneti-
cally stable during the manufacturing process. The highly
sensitive TaqMAMA of the 59NCR-57 locus demonstrated
minimal or undetectable reversion in the MVS of each
DENVax serotype. The 59NCR-57 reversion rates of the
DENVax MVS (P8) were significantly lower than the 59NCR-
57 reversion rates that evolved in research-grade vaccine
candidates after 8-serial passages in Vero cells (6–45%
reversion) [14]. The retention of the 3 attenuation loci were
also confirmed in the P10 seeds that were passaged twice from
the MVS (data not shown). Thus, the strategy for large-scale
manufacturing of the DENVax seeds presented in this report
resulted in genetically stable vaccine seeds which retained the
expected markers of attenuation.
Figure 4. Neurovirulence in newborn mice. Pooled results of numerous experiments summarizing the neurovirulence of wt DENV-2 16681 virus
in CDC-ICR (n = 72) and Taconic-ICR (n = 32) newborn mice challenged ic with 104 pfu of the virus (A). Neurovirulence of DENVax MVS tested in
Taconic-ICR mice with a dose of 104 pfu (B) or 103 pfu (C). The numbers of animals tested per group in one experiment (n = 16) or two pooled
experiments (n = 31 or 32) are indicated.
doi:10.1371/journal.pntd.0002243.g004
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Complete evaluation of the phenotypic markers of viral
attenuation, including small plaque phenotype, temperature
sensitivity, reduced replication in mosquito cells, reduced infec-
tion/dissemination/transmission by mosquitoes, and attenuation
in newborn ICR mice, were assessed for the MVS stocks.
Although we cannot totally rule out that the slight phenotype
variations between the DENVax and original research vaccine
viruses were caused by the additional mutations that evolved in
DENVax MVS stocks, none of the variations was very significant
and all of the DENVax were still considerably attenuated relative
to their wt counterparts. It will be important to analyze the clinical
study outcomes in the context of genome sequences of clinical
vaccine lots, and perhaps, viruses isolated from vaccinees to fully
evaluate the safety and genetic stability of DENVax in humans.
Vector competence is an important safety component for live-
attenuated flavivirus vaccine viruses [16–21]. We have previously
tested the research-grade DENV-2 PDK-53-VV45R virus and wt
reversion mutant derivatives in Ae. aegypti, and found that the NS1-
53-Asp attenuating mutation was the dominant determinant for
impaired replication in the mosquito [22]. The other two major
attenuation loci of the DENV-2 PDK-53 vaccine, nucleotide
59NCR-57-T and NS3-250-Val, also exhibited some inhibiting
effect on replication in mosquitoes, thus providing additional,
redundant restrictions for mosquito vector competence. This study
is the first to report the mosquito oral and IT infection and
replication for all four DENVax strains. DENVax-1, -2, and -3 did
not infect any Ae. aegypti mosquitoes through oral infection
(Table 4). The DENVax-4 infected only 3.6% of orally exposed
mosquitoes, a level significantly lower than that of the wt DENV-4
with a replicative mean titer in the mosquito bodies lower than
that of wt DENV-4 infected mosquitoes. Most importantly, no
DENVax-4 was detected in the legs of the infected mosquitoes,
suggesting that DENVax-4 was not able to escape from the midgut
barriers following oral infection. The infection rates for the
DENVax-1, -2, and -4 were all significantly less than their wt
counterparts, but the difference was not significant between
DENVax-3 and wt DENV-3 16562 due to the very low infection
rates for both viruses. Compared to other wt strains of DENV
assessed in Ae. aegypti collected from the same Mae Sot Province,
Thailand [21], the parental wt DENV strains used for engineering
our DENVax appeared to have lower infection and dissemination
rates following oral exposure. The wt DENV-1 PUO359, DENV-
2 PUO218, DENV-3 PaH881/88, and DENV-4 1288 used for
engineering the yellow fever virus (YFV) 17D vaccine-based
ChimeriVax-DEN vaccines had infection rates ranging 47–77%.
In contrast, the YFV 17D vaccine cannot infect Ae. aegypti [21].
Although the ChimeriVax strains contained the prM-E from these
highly infectious wt DENV, the ChimeriVax retain the mosquito
attenuation phenotype of their YFV 17D replicative backbone
[21]. Our results also indicated that the mosquito attenuation
phenotype of the DENV-2 PDK-53 backbone was maintained in
the DENVax strains. In addition, using the wt DENV strains with
lower mosquito-infectivity in our constructs provides an additional
safety feature for DENVax.
The oral infection results showed clearly that the DENVax had
minimum mosquito infectivity and dissemination capacity. In
addition, we performed the more sensitive IT inoculation to infect
the mosquito body directly. This allowed us to establish a model to
evaluate the potential of transmission if, by rare chance, any of the
DENVax were able to overcome both MIB and MEB. Our results
demonstrated that all four DENVax viruses had non-detectable or
minimal mosquito transmission potential compared to their wt
counterparts even with such an artificially high infection rate.
DENVax transmission could only theoretically occur if (1) a vector
feeds on a vaccinee having a sufficient viremic titer to infect
mosquito midgut epithelium; (2) the virus is capable of replicating
in these cells and subsequent dissemination out of the midgut; and
(3) the disseminated virus can replicate in salivary gland and
expectorate sufficient virus in saliva for transmission. The
threshold of human viremia required to infect mosquitoes has
not been established adequately, but human viremia can be 106–
108 mosquito infectious dose50 (MID50)/ml after natural wt
DENV infection [23,24]. This MID50 was based on direct IT
inoculation of mosquitoes with diluted human plasma. A previous
study analyzing DENVax in nonhuman primates (NHP) indicated
that viremic titers following DENVax immunization were very low
(less than 2.4 log10 pfu/ml) and lasted for 2–7 days [25]. Given the
low viremia levels and the low mosquito infection, dissemination,
and transmission capacity of DENVax, it is unlikely that these
vaccine viruses could be transmitted by mosquitoes in nature.
Unlike some other flaviviruses, such as Japanese encephalitis
virus and YFV that can cause encephalitis in humans and show
neuropathic effects in the NHP neurovirulent test, wt DENVs are
generally not neurotropic in humans and the NHP [26,27].
Previous neurovirulence studies of DENVs, including the wt
DENV-1 16007, DENV-2 16681, DENV-3 16562, and DENV-4
1036 that were the parental viruses for engineering the 4 DENVax
strains, showed that they caused only minimal neuropathophysiol-
ogy after intracerebral injection into NHP [26,28–31]. In addition,
the DENVax seeds were not generated in a manner that could
enhance neurovirulence; thereby they would not be expected to be
neuropathologic in a NHP test. Infant mice have been demon-
strated to be an accurate surrogate for the neurovirulence test of
DENV vaccines in NHP previously [32], and the newborn mouse
neurovirulence model reported in this study provided further
support that certain young suckling mice can be a sensitive model
for DENV vaccine evaluation.
In summary, we have successfully developed a unique manufac-
turing strategy to optimize the genetic stability and safety of the
manufactured DENVax MVS. Since the main attenuation loci of
the DEN-2 PDK-53-based DENVax have been well characterized
previously [6,12], we were able to integrate genome sequence and
the TaqMAMA to identify optimal pre-master seeds for preparation
of the MVS. Our results highlight the advantage of employing
strategically designed live-attenuated vaccines with well-defined
molecular attenuation determinants in predicting vaccine safety. In
addition to the attenuation characteristics analyzed and described in
this report, we have tested and confirmed the safety and
immunogenicity of the DENVax MVS in AG129 mice [33] and
NHP [25]. The present study described here and the ongoing
clinical trial studies of DENVax will provide critical information to
further evaluate the safety and efficacy of tetravalent DENVax as a
vaccine to protect humans against dengue.
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